uniQure N.V. - Ordinary Shares (QURE): Price and Financial Metrics


uniQure N.V. - Ordinary Shares (QURE): $25.65

-0.38 (-1.46%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add QURE to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

QURE POWR Grades

  • QURE scores best on the Sentiment dimension, with a Sentiment rank ahead of 71.23% of US stocks.
  • QURE's strongest trending metric is Value; it's been moving down over the last 177 days.
  • QURE ranks lowest in Stability; there it ranks in the 5th percentile.

QURE Stock Summary

  • Of note is the ratio of UNIQURE NV's sales and general administrative expense to its total operating expenses; merely 9.27% of US stocks have a lower such ratio.
  • With a price/sales ratio of 19.55, UNIQURE NV has a higher such ratio than 94.16% of stocks in our set.
  • As for revenue growth, note that QURE's revenue has grown -87.72% over the past 12 months; that beats the revenue growth of merely 1.44% of US companies in our set.
  • Stocks that are quantitatively similar to QURE, based on their financial statements, market capitalization, and price volatility, are ENTA, RAPT, SELB, RNA, and XENE.
  • QURE's SEC filings can be seen here. And to visit UNIQURE NV's official web site, go to www.uniqure.com.

QURE Valuation Summary

  • QURE's price/earnings ratio is -9.7; this is 141.45% lower than that of the median Healthcare stock.
  • QURE's EV/EBIT ratio has moved down 7.2 over the prior 70 months.

Below are key valuation metrics over time for QURE.

Stock Date P/S P/B P/E EV/EBIT
QURE 2022-12-02 19.8 2.9 -9.7 -7.9
QURE 2022-12-01 20.0 2.9 -9.8 -8.0
QURE 2022-11-30 20.2 2.9 -9.9 -8.0
QURE 2022-11-29 19.6 2.9 -9.6 -7.7
QURE 2022-11-28 20.8 3.0 -10.2 -8.4
QURE 2022-11-25 20.5 3.0 -10.0 -8.2

QURE Growth Metrics

    The 2 year cash and equivalents growth rate now stands at 53.46%.
  • Its 4 year net income to common stockholders growth rate is now at -69.58%.
  • Its 2 year net cashflow from operations growth rate is now at 388.52%.
Over the past 15 months, QURE's revenue has gone down $438,768,000.

The table below shows QURE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 61.429 -137.47 -125.388
2022-06-30 61.969 -128.636 -114.062
2022-03-31 525.34 303.521 324.467
2021-12-31 524.002 287.959 329.589
2021-09-30 500.397 297.874 320.682
2021-06-30 500.197 303.322 303.438

QURE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • QURE has a Quality Grade of C, ranking ahead of 27.42% of graded US stocks.
  • QURE's asset turnover comes in at 0.884 -- ranking 28th of 682 Pharmaceutical Products stocks.
  • OVID, ACER, and SCYX are the stocks whose asset turnover ratios are most correlated with QURE.

The table below shows QURE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.884 0.954 1.955
2021-06-30 1.088 0.954 2.048
2021-03-31 0.105 1.000 -1.161
2020-12-31 0.101 1.000 -1.210
2020-09-30 0.015 1.000 -1.522
2020-06-30 0.012 1.000 -1.234

QURE Price Target

For more insight on analysts targets of QURE, see our QURE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $66.92 Average Broker Recommendation 1.37 (Strong Buy)

QURE Stock Price Chart Interactive Chart >

Price chart for QURE

QURE Price/Volume Stats

Current price $25.65 52-week high $30.41
Prev. close $26.03 52-week low $12.52
Day low $25.37 Volume 682,400
Day high $26.30 Avg. volume 634,169
50-day MA $20.69 Dividend yield N/A
200-day MA $18.78 Market Cap 1.20B

uniQure N.V. - Ordinary Shares (QURE) Company Bio


uniQure is a biopharmaceutical company, developing adeno-associated virus (AAV) based gene therapies through its technology platform for multiple therapeutic areas. The company was founded in 1998 and is based in Amsterdam, the Netherlands.


QURE Latest News Stream


Event/Time News Detail
Loading, please wait...

QURE Latest Social Stream


Loading social stream, please wait...

View Full QURE Social Stream

Latest QURE News From Around the Web

Below are the latest news stories about UNIQURE NV that investors may wish to consider to help them evaluate QURE as an investment opportunity.

uniQure Highlights Therapeutic Potential of AMT-260 in Refractory Temporal Lobe Epilepsy (rTLE) at Virtual Research & Development Event

~ IND Submission and Clinical Development Expected to Begin in 2023 ~ ~ Advancements in Manufacturing and Technology Platform Also Highlighted ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 29, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, hosted a virtual investor event focused on AMT-260, an AAV gene therapy for refractory temporal lobe epilepsy (rTLE) and other focal epil

Yahoo | November 29, 2022

Why Shares of uniQure Rose 14.61% on Wednesday

Shares of uniQure (NASDAQ: QURE) climbed 14.61% on Wednesday. The stock jumped after the Food and Drug Administration (FDA), on Tuesday, approved Hemgenix (etranacogene dezaparvovec-drlb), a one-time gene therapy for hemophilia B. It was developed by uniQure, but CSL will commercialize the therapy. Hemophilia B, also known as Christmas disease, is rare.

Yahoo | November 23, 2022

The FDA Just Approved Its Most Expensive Drug Ever — Sending UniQure Stock On A Warpath

The FDA just approved its most expensive drug ever — a hemophilia gene therapy from CSL and UniQure — and QURE stock popped Wednesday.

Yahoo | November 23, 2022

For Lexington's UniQure, hemophilia gene therapy approval is a comeback story

For Lexington-based UniQure NV, Hemgenix — the first drug approved by the FDA for hemophilia B — is a comeback story.

Yahoo | November 23, 2022

uniQure (QURE) Partner Gets FDA Nod for Hemophilia B Gene Therapy

uniQure (QURE) shares rise after its partner CSL Limited received FDA nod for one-time gene therapy, Hemgenix, for treating adults with Hemophilia B.

Yahoo | November 23, 2022

Read More 'QURE' Stories Here

QURE Price Returns

1-mo 33.32%
3-mo 23.02%
6-mo 65.80%
1-year -8.00%
3-year -61.17%
5-year 50.71%
YTD 23.67%
2021 -42.60%
2020 -49.58%
2019 148.65%
2018 47.12%
2017 249.82%

Continue Researching QURE

Want to see what other sources are saying about uniQure NV's financials and stock price? Try the links below:

uniQure NV (QURE) Stock Price | Nasdaq
uniQure NV (QURE) Stock Quote, History and News - Yahoo Finance
uniQure NV (QURE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7771 seconds.